What Is Endomyocardial Biopsy After Heart Transplant?

A donor heart doesn’t come with a warning light. Doctors need a direct look at the tissue itself to know if the body’s turning on it, not just how the patient feels day to day. That’s the job of a thin device called a bioptome, threaded up through a vein in the neck to pull tiny samples of heart muscle. Minimally invasive, yes, but it gets repeated again and again in the months and years after surgery. Blood tests have improved a lot. This is still the one doctors trust most.

According to Dr. Vishal Khullar, a leading Heart Transplant Surgeon in Mumbai, “Patients often ask why we keep doing biopsies when they feel completely fine. Rejection frequently shows no symptoms early on. The biopsy tells us what the patient’s body can’t.”

The schedule isn’t arbitrary. It follows how rejection risk actually moves over time.

First few weeks, weekly biopsies: Rejection risk peaks early, so biopsies happen roughly once a week right after surgery. This tapers as the new heart settles in.

First year, gradually spaced out: Frequency drops to every few weeks, then monthly, as the risk curve flattens through the first twelve months.

Beyond year one, occasional checks: Biopsies become far less frequent, often just a few times a year, sometimes replaced by blood-based rejection tests in stable patients.

Symptom-triggered biopsies: Any sign of possible rejection, fatigue, breathlessness, irregular heartbeat, can prompt an unscheduled biopsy regardless of where a patient sits in the usual timeline.

How well rejection gets caught and managed shapes long-term outcomes more than most patients realize. Our piece on life expectancy after transplant covers what that actually means for survival.

Dr. Vishal Khullar is a Cardiovascular and Thoracic Surgeon with over 30 years of experience and more than 7,000 cardiac procedures, including heart transplantation and long-term post-transplant care. His training includes time at Cleveland Clinic and a role as Senior Associate Consultant at Mayo Clinic in the US. His practice covers the full transplant follow-up pathway, including endomyocardial biopsy surveillance and management of rejection when it’s detected.

1. PMC (NIH): Routine Surveillance Endomyocardial Biopsy for the Detection of Cellular Rejection Beyond 2 Years After Cardiac Transplantation
2. PMC (NIH): Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling

Disclaimer: This blog is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment; please consult a qualified doctor for any health concerns.